ClariVest Asset Management LLC increased its position in Emergent Biosolutions Inc. (NYSE:EBS) by 15.4% during the second quarter, Holdings Channel reports. The institutional investor owned 91,369 shares of the biopharmaceutical company’s stock after buying an additional 12,200 shares during the period. ClariVest Asset Management LLC’s holdings in Emergent Biosolutions were worth $2,570,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of EBS. Rice Hall James & Associates LLC increased its stake in shares of Emergent Biosolutions by 1.4% in the second quarter. Rice Hall James & Associates LLC now owns 279,227 shares of the biopharmaceutical company’s stock worth $7,852,000 after buying an additional 3,930 shares in the last quarter. Capital Fund Management S.A. acquired a new stake in shares of Emergent Biosolutions during the second quarter worth $439,000. Alps Advisors Inc. increased its stake in shares of Emergent Biosolutions by 19.2% in the second quarter. Alps Advisors Inc. now owns 68,308 shares of the biopharmaceutical company’s stock worth $1,921,000 after buying an additional 11,000 shares in the last quarter. GW&K Investment Management LLC increased its stake in shares of Emergent Biosolutions by 12.3% in the second quarter. GW&K Investment Management LLC now owns 112,307 shares of the biopharmaceutical company’s stock worth $3,158,000 after buying an additional 12,274 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in shares of Emergent Biosolutions by 1.4% in the second quarter. American Century Companies Inc. now owns 180,590 shares of the biopharmaceutical company’s stock worth $5,078,000 after buying an additional 2,533 shares in the last quarter. 89.93% of the stock is currently owned by institutional investors and hedge funds.
Shares of Emergent Biosolutions Inc. (NYSE:EBS) traded up 2.773% on Monday, hitting $32.055. The stock had a trading volume of 187,542 shares. The firm has a 50-day moving average of $28.28 and a 200 day moving average of $34.07. The company has a market capitalization of $1.30 billion, a PE ratio of 22.929 and a beta of 1.12. Emergent Biosolutions Inc. has a 1-year low of $26.12 and a 1-year high of $44.38.
Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.01. Emergent Biosolutions had a return on equity of 11.93% and a net margin of 11.61%. The company earned $101.49 million during the quarter, compared to analysts’ expectations of $111.20 million. During the same quarter last year, the firm posted $0.36 earnings per share. The firm’s revenue was down 19.5% on a year-over-year basis. On average, equities analysts anticipate that Emergent Biosolutions Inc. will post $1.03 earnings per share for the current fiscal year.
A number of equities research analysts have weighed in on the company. Wells Fargo & Co. set a $41.00 target price on Emergent Biosolutions and gave the company a “buy” rating in a report on Saturday, October 1st. Zacks Investment Research downgraded Emergent Biosolutions from a “hold” rating to a “sell” rating in a report on Tuesday, July 12th. Singular Research reduced their target price on Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating on the stock in a report on Tuesday, June 28th. Cowen and Company reaffirmed a “hold” rating and issued a $33.00 target price on shares of Emergent Biosolutions in a report on Sunday, August 7th. Finally, JPMorgan Chase & Co. reduced their target price on Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating on the stock in a report on Friday, August 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $40.17.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc. (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.